John Blankenhorn

John Blankenhorn

Expertise: Biochemistry, biotechnology and pharmaceutical research

John Blankenhorn has been a researcher since 2016 and has years of experience and publications on the topics of biochemistry, biotechnology, and pharmaceutical research. His main interests are the application of biology and biotechnology to our daily lives, as well as the use of Machine Learning and AI to speed up research and development in the life sciences. He currently works at Emory University studying the structural basis of Alzheimer’s Disease.

Recent Articles

7 Biotech Stocks to Get In Now Before Investors Catch On

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

3 Biotech Stocks Ready to Break Out in 2024

Still, many biotech stocks to buy are positioned well for the coming quarter and new year. These show amazing drug portfolios, promising growth potential, and world-class technology.

The Future of Work: 3 Ways Automation and AI Will Change the Job Market

The future of AI will bring drastic changes to the workplace. Dive into these automation trends, and don't get left behind.

Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns

These biotech stocks, Thermo Fisher, Novo Nordisk, and Eli Lilly, will bring consistent returns in the volatile biotech sector.

Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs

The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars.